RTHM

RTHM RTHM is a secure health platform that makes it easy to gather your records, connect the dots with AI, and affordably access treatments.

Want to know how the latest Long COVID research relates to your case?Sign up for RTHM to receive studies curated to your...
05/27/2026

Want to know how the latest Long COVID research relates to your case?

Sign up for RTHM to receive studies curated to your health conditions, symptoms, and topics of interest.

This week, here are five recent publications related to Long COVID, ranging from immune and vascular changes to viral reactivation.

Don’t have Long COVID? You can select conditions, symptoms and topics that are relevant to you and receive a curated research email about those items weekly.

Sign up for weekly curated research emails here: https://www.rthm.com/research-corner/tags

Have you tried ketotifen for Long COVID, ME/CFS, or MCAS-related symptoms?According to our data from patients prescribed...
05/22/2026

Have you tried ketotifen for Long COVID, ME/CFS, or MCAS-related symptoms?

According to our data from patients prescribed ketotifen through RTHM, 41% reported improvements in their symptoms, and 32% of those who improved experienced significant benefits.

Ketotifen works as an oral antihistamine and mast cell stabilizer, helping calm overactive immune responses that may contribute to allergic symptoms, food intolerances, poor sleep, GI symptoms, and post-exertional malaise (PEM).

Swipe to see why some RTHM users are finding ketotifen to be a helpful tool in managing complex chronic illness.

You can explore whether compounded oral ketotifen is right for you through a clinician-reviewed treatment assessment. Click the link in our bio to get started.

05/20/2026

In POTScast Ep 306, Dr. Jennifer Curtin and patient advocate Charlie McCone explain how the Long COVID Treatment Guide, a collaboration between RTHM and Patient Led Research Collaborative (PLRC), helps patients and clinicians have meaningful conversations about treatment options that can be considered as part of a personalized care plan.

Here, Charlie explains that having the evidence base for each treatment gathered in one place helped his care in an unexpected way, and that this guide may help newer and more knowledgeable patients alike.

A recent study published in Cell Reports Medicine adds to a growing set of antibody-transfer studies that suggest autoim...
05/14/2026

A recent study published in Cell Reports Medicine adds to a growing set of antibody-transfer studies that suggest autoimmunity could be playing a role in driving Long COVID symptoms.

Researchers isolated IgG antibodies (a major class of antibodies) from people with Long COVID and transferred them into healthy mice. In some conditions, these antibodies can become autoantibodies, meaning they mistakenly target the body’s own tissues instead of (or in addition to) something foreign like a virus or bacterium.

After receiving IgG from Long COVID patients, the mice developed symptoms that resembled some of those seen in Long COVID, including fatigue-like behavior and changes in pain sensitivity. Antibodies from different subgroups of Long COVID patients caused different symptom patterns in the mice, suggesting that different antibody profiles may contribute to different presentations of Long COVID.

The findings do not prove that all Long COVID is caused by autoantibodies, and mouse studies still need to be validated in humans. But the studies do add to a growing number of antibody-transfer studies that provide functional evidence that antibodies from Long COVID patients may directly contribute to symptoms. More research in this area could potentially open the door to more targeted treatment approaches based on antibody subgroups, including therapies that remove, block, or neutralize harmful IgG.

Read the full study: https://doi.org/10.1016/j.xcrm.2026.102693

Patient-Led Research Collaborative (PLRC) and RTHM Clinic recently released the Long COVID Treatment Guide to support mo...
05/07/2026

Patient-Led Research Collaborative (PLRC) and RTHM Clinic recently released the Long COVID Treatment Guide to support more informed conversations between patients and their clinicians.

The guide covers over 30 different interventions. Today, we’re highlighting maraviroc, a medication that has shown promise for people with Long COVID, especially those experiencing cognitive impairment, fatigue, post-exertional malaise, and other inflammation-related symptoms.

Maraviroc may help by targeting immune dysregulation through the monocytic-endothelial-platelet axis, a pathway believed to play a role in Long COVID symptoms. In research, maraviroc paired with pravastatin was associated with improvements in neurological, autonomic, respiratory, cardiac, and fatigue symptoms, along with vascular markers.

A patient survey found 64% of people reported a slight to significant improvement with maraviroc. In the Harvard/Stanford TREATME study, 42% of individuals with Long COVID who tried maraviroc reported moderate to much better improvement in symptoms. A clinical trial is also underway at Mount Sinai to further evaluate its potential in Long COVID.

As with all treatments in the guide, maraviroc is prescribed off-label and should be discussed with a clinician to determine whether it is appropriate for an individual case. The treatment guide is an evidence-based resource hub designed to make research easier to understand so patients and clinicians can make informed decisions together.

If you want a direct link to download the guide, comment below, and we’ll send you a DM.

If fatigue, brain fog, or crashes make everything feel harder, strengthening the basics can make a real difference.Suppo...
05/01/2026

If fatigue, brain fog, or crashes make everything feel harder, strengthening the basics can make a real difference.

Supporting mitochondrial function is a core piece of many Long COVID and ME/CFS treatment plans. Building a stronger foundation is one of the most supportive first steps you can take, and this supplement pack was created with that in mind.

Each supplement is clinician-curated and selected based on real-world outcomes to support mitochondrial function, improve oxidative stress, and help with symptoms like fatigue, brain fog, and PEM.

Think of it as creating the base your body needs so everything else in your treatment plan has a steadier place to land.

Swipe through to explore how each supplement may help support mitochondrial health.

Visit our blog to learn more: https://rthm.com/mito-pack

You don't have to take our word for it. Let our users do the talking.Swipe to see what the RTHM community is saying on o...
04/28/2026

You don't have to take our word for it. Let our users do the talking.

Swipe to see what the RTHM community is saying on our socials.

We've been reading your comments, DMs, and posts, and we're grateful for the feedback you’ve shared.

RTHM is a HIPAA-compliant platform that securely brings all your data into one place. It uses research-grounded, IACC-informed AI to surface patterns, explain findings, and suggest best next steps in your care.

For many people, it’s the first time their case feels organized, actionable, and truly understood.

It’s not just AI – RTHM is purpose-built AI for people living with ME/CFS, Long COVID, POTS, MCAS, EDS, and other complex chronic conditions.

Try it for yourself at rthm.com.

Patient-Led Research Collaborative (PLRC) and RTHM Clinic recently released the Long COVID Treatment Guide to support mo...
04/21/2026

Patient-Led Research Collaborative (PLRC) and RTHM Clinic recently released the Long COVID Treatment Guide to support more informed conversations between patients and their clinicians.

The guide covers over 30 different interventions. Today, we’re highlighting rapamycin, a medication that has shown promise for those with ME/CFS and Long COVID—particularly patients experiencing fatigue and post-exertional malaise (PEM).

In a phase one trial in people with ME/CFS, weekly rapamycin doses of up to 6 mg were associated with significant improvements in fatigue, sleep, and orthostatic intolerance over three months. Researchers believe this may be related to rapamycin’s effects on autophagy and mTOR signaling, which are areas of growing interest in ME/CFS and Long COVID. A clinical trial studying low dose rapamycin in people with ME/CFS and people with Long COVID is also currently underway.

In the Harvard/Stanford TREATME study, 22% of individuals with Long COVID or ME/CFS who tried rapamycin reported moderate to much better symptom improvement.

As with all treatments in the guide, rapamycin is prescribed off-label and should be discussed with a clinician to determine whether it is appropriate for an individual case. It may also require lab monitoring, such as CMP, CBC, lipids, fasting glucose, A1C, and fasting insulin, since it can worsen lipids, liver enzymes, and insulin resistance in some people, especially early on.

The Treatment Guide is an evidence-based resource hub that can help inform clinicians and patients about treatments that could be tried today.

Download the guide here: https://www.rthm.com/treatmentguide

Have you tried Low Dose Naltrexone (LDN) for Long COVID, ME/CFS, or other chronic illness symptoms? Please share in comm...
03/27/2026

Have you tried Low Dose Naltrexone (LDN) for Long COVID, ME/CFS, or other chronic illness symptoms? Please share in comments.

According to real-world data, 57% of RTHM Platform users who had taken LDN reported improvements, and 38% of those described the benefits as significant.

The most commonly reported improvements were reduced fatigue, improved mental clarity, decreased aches and pains, and reduced post-exertional malaise. Many patients saw more noticeable benefits at the 90-day mark than after just 30 days, showing that LDN can take time to reach full effect.

LDN is often started at very low doses (0.5–1.5 mg) and gradually titrated up to a tolerated dose of 3–4.5 mg. It works by modulating immune and inflammatory responses, offering support for some of the most challenging symptoms of complex chronic illness.
Swipe through to see more and learn whether LDN could be a helpful part of your treatment plan.

You can explore potential treatments like LDN through RTHM or join our email list for updates on research and treatment access. Link in bio to get started or sign up.

In a recent op-ed published by The Sick Times, “A new aid in the doctor’s office: Introducing the Long COVID Treatment G...
03/25/2026

In a recent op-ed published by The Sick Times, “A new aid in the doctor’s office: Introducing the Long COVID Treatment Guide,” Dr. Letícia Soares from PLRC and Dr. Jennifer Curtin from RTHM discuss the treatment guide assembled over the past year for patients to explore potential treatment options for Long COVID. They highlight that there are prospective treatment approaches available today that may help reduce symptoms and improve quality of life while we wait for more RCTs.

The treatment guide contains 24 prescription medications, as well as select over-the-counter medications, procedures, and lifestyle tools. Note, it is not an exhaustive list, nor is it intended to serve as medical advice.

The guide was designed to support both patients and clinicians in having conversations about prospective off-label treatments during limited appointment times, while also helping to close gaps in awareness around the evolving evidence base.

We hope this resource can help patients evaluate the options available to them and can inform clinicians on the supporting evidence for off-label treatments for Long COVID.

Read the full story: https://thesicktimes.org/2026/03/12/a-new-aid-in-the-doctors-office-introducing-the-long-covid-treatment-guide/

A national study found that children with Long COVID are more likely to struggle in school and miss significant amounts ...
03/19/2026

A national study found that children with Long COVID are more likely to struggle in school and miss significant amounts of class due to illness.

Researchers analyzed survey data from more than 11,000 U.S. children ages 5–17, comparing kids with Long COVID symptoms lasting longer than three months to those who never had Long COVID.

Children with Long COVID reported higher rates of learning difficulties (19.8% vs 10.4%), as well as more problems with memory, concentration, and depression.

They were also far more likely to miss school because of illness. About 13.9% experienced chronic illness-related absenteeism (missing 18+ school days per year), compared with 3.5% of children without Long COVID. Children who had Long COVID had about 2.5 times the odds of chronic illness-related absenteeism.

These findings suggest Long COVID may affect not just health, but also learning, development, and school participation for some children.

👉 Read the full study: https://doi.org/10.3201/eid3114.251035

Authors: Nicole D. Ford, Regina M. Simeone, Caroline Pratt, Sharon Saydah

Address

2261 Market Street #10535
San Francisco, CA
94114

Website

https://linktr.ee/rthm_health

Alerts

Be the first to know and let us send you an email when RTHM posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category